Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.76 |
| ▸ | PPARD | Q03181 | 10/20 | 0.76 |
| ▸ | PPARA | Q07869 | 10/20 | 0.76 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.39 |
| ▸ | PDE5A | O76074 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935503 | 0.96 | PPARG (0.75) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6935493 | 0.94 | PPARG (0.85) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6936719 | 0.94 | PPARG (0.85) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6938540 | 0.92 | PPARG (0.89) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6938524 | 0.92 | PPARG (0.89) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6933724 | 0.92 | PPARG (0.66) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6933722 | 0.92 | PPARG (0.66) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6934160 | 0.90 | PPARG (0.74) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6939101 | 0.89 | PPARG (0.73) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6939664 | 0.88 | PPARG (0.68) | PPARGPPARDPPARANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888278-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | claimed |
| EP-0888278-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-0882029-B1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6090836-A | DIETETICS; ADJUSTMENT OF TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |